Philip Connell

Philip Connell is a Professor at the University of Chicago in the Radiation and Cellular Oncology department. Since 2000, he has been affiliated with the University through residency and faculty positions, currently serving as Associate Department Chair for Academic Affairs. His clinical expertise spans sarcomas, thoracic cancers, and pediatric malignancies, with ongoing recognition as a top doctor by Newsweek and Chicago Magazine since 2015.

Education:

• B.S. in Chemical Engineering, Tufts University (1991)
• M.D., New York Medical College (1995)
• Internship in Internal Medicine, St. Vincent's Hospital (1996)
• Residency in Radiation Oncology, University of Chicago (2000)
• NIH Research Fellowship in Cancer Biology (2001)

Research Focus: Dr. Connell's research program centers on identifying molecular markers of treatment resistance and developing novel anti-cancer agents that target DNA repair mechanisms. His work employs high-throughput assays to discover compounds impacting chemotherapy/radiotherapy outcomes, with a particular focus on RAD51 inhibition and noncanonical NF-?B signaling. Publications span biochemistry, clinical oncology, radiation therapy, and pharmacology, reflecting interdisciplinary approaches to cancer treatment.

Scientific Awards:

• 1997 American Society of Clinical Oncology Merit Award
• 1999 Roentgen Society and American Brachytherapy Society Research Awards
• 2003 Samuel Hellman Teaching Award
• 2004-2005 American Society for Therapeutic Radiology and Oncology Junior Faculty Fellowship
• 2016 Best basic/translational science award at ASTRO Annual Meeting

Leadership & Grants: Principal Investigator on NIH grants R01CA142642 (RAD51 Inhibitors for Chemotherapy/Radiation Therapy) and R21CA124557 (DNA Repair Inhibition in Pancreatic Cancer). Served as advisor/supervisor on RSNA Resident/Fellow Grant (2020-2022).